PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells.

导出 OA

翻译打印收藏纠错

作者： Otto,Kauko ^[1] ; Caitlin M,O'Connor ^[2] ; Evgeny,Kulesskiy ^[3] ; Jaya,Sangodkar ^[4] ; Anna,Aakula ^[5] ; Sudeh,Izadmehr ^[6] ; Laxman,Yetukuri ^[1] ; Bhagwan,Yadav ^[6] ; Artur,Padzik ^[1] ; Teemu Daniel,Laajala ^[5] ; Pekka,Haapaniemi ^[1] ; Majid,Momeny ^[5] ; Taru,Varila ^[7] ; Michael,Ohlmeyer ^[1] ; Tero,Aittokallio ^[1] ; Krister,Wennerberg ^[1] ; Goutham,Narla ^[6] ; Jukka,Westermarck ^[5]

作者单位： Turku Centre for Biotechnology, University of Turku and Åbo Akademi University, 20520 Turku, Finland. ^[1] Institute of Biomedicine, University of Turku, 20520 Turku, Finland. ^[2] TuBS and TuDMM Doctoral Programmes, University of Turku, 20520 Turku, Finland. ^[3] Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH 44106-7285, USA. ^[4] Institute for Molecular Medicine Finland, University of Helsinki, 00014 Helsinki, Finland. ^[5] Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. ^[6] Department of Mathematics and Statistics, University of Turku, 20520 Turku, Finland. ^[7] Turku Centre for Biotechnology, University of Turku and Åbo Akademi University, 20520 Turku, Finland. jukwes@utu.fi. ^[8]